• <input id="ycg2u"></input>
    <legend id="ycg2u"></legend>
    <strong id="ycg2u"><u id="ycg2u"></u></strong>
  • Enable Accessibility Enable Accessibility

    Takeda Announces Candidates for New Directors

    March 31, 2021

    OSAKA, Japan, March 31, 2021, --- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced candidates for its Board of Directors that will be proposed at the 145th Ordinary General Meeting of Shareholders to be held on June 29, 2021.

    Proposed Change in Directors
    Takeda is committed to exercising strong corporate governance practices to promote the long-term interests of shareholders and all its stakeholders as well as strengthening its Board of Directors and management accountability. As part of this commitment, the Board of Directors decided that all members of the Audit and Supervisory Committee will be external directors to further enhance the independence of the Committee. Mr. Yasuhiko Yamanaka, Director, a member of the Audit and Supervisory Committee will retire from his current role effective upon the conclusion of the 145th Ordinary General Meeting of Shareholders and become an advisor for one year to ensure smooth transition to the Committee consisting of fully external Directors.

    Also, Takeda is pleased to nominate Mr. Masami Iijima from Mitsui & Co., Ltd. to join as an External Director who will be a substitute member of the Audit and Supervisory Committee. Joining Mitsui & Co., Ltd. in 1974,  Mr. Iijima has held various senior roles of increasing responsibility, and recently served as Representative Director, Chairman of the Board of Directors. He will continue serve as Director until June 18 when he will be nominated as Counselor. Mr. Masami IIjima is also currently serving as External Director for Ricoh Company, Ltd., SoftBank Group Corp., and Isetan Mitsukoshi Holdings Ltd., as well as Counsellor of Bank of Japan.

    As already announced, Mr. Masato Iwasaki, who started with Takeda in 1985, will transition from the role of president of Japan Pharma Busines Unit to the role of Japan General Affairs on April 1, 2021. Further, the Board of Directors has resolved that upon Mr. Iwasaki’s election as a Director at the 145th Ordinary General Meeting of Shareholders, he will then be appointed as another Representative Director at a Board of the Directors meeting immediately following the 145th Ordinary General Meeting of Shareholders. In his new role as Japan General Affairs, Mr. Iwasaki will chair and coordinate a network representing all of Takeda's functions in Japan to maintain and enhance the Company’s reputation in Japan and to ensure one voice to our external stakeholders in Japan.

    Candidates for Directors Who are Not Audit and Supervisory Committee Members

    Name

    Category

    Expected Role

    Christophe Weber

    Internal

    Existing

    Representative Director,
    President & Chief Executive Officer

    Masato Iwasaki

    Internal

    Existing

    Representative Director, Japan General Affairs

    Andrew Plump

    Internal

    Existing

    Director, President, Research & Development

    Constantine Saroukos

    Internal

    Existing

    Director, Chief Financial Officer

    Masahiro Sakane

    External

    Existing

    External Director, Chair of the Board Meeting
    Chair of the Nomination Committee

    Olivier Bohuon

    External

    Existing

    External Director
    Member of the Compensation Committee

    Jean-Luc Butel

    External

    Existing

    External Director
    Member of the Nomination Committee

    Ian Clark

    External

    Existing

    External Director
    Member of the Compensation Committee

    Yoshiaki Fujimori

    External

    Existing

    External Director
    Member of the Compensation Committee

    Steven Gillis

    External

    Existing

    External Director
    Member of the Nomination Committee

    Shiro Kuniya

    External

    Existing

    External Director

    Toshiyuki Shiga

    External

    Existing

    External Director
    Member of the Nomination Committee


    Candidate for Director Who is Audit and Supervisory Committee Member

    Name

    Category

    Expected Role

    Masami Iijima

    External

    New

    External Director, Audit and Supervisory Committee Member


    The following three Directors who are Audit and Supervisory Committee members were elected at the 144th Ordinary General Meeting of Shareholders held in 2020 and their terms of office will continue until the 146th Ordinary General Meeting of Shareholders held in 2022.

    Name

    Category

    Role

    Koji Hatsukawa

    External

    Existing

    External Director, Chairperson of Audit and Supervisory Committee

    Emiko Higashi

    External

    Existing

    External Director, Audit and Supervisory Committee Member
    Chair of the Compensation Committee

    Michel Orsinger

    External

    Existing

    External Director, Audit and Supervisory Committee Member
    Member of the Nomination Committee


    About Takeda Pharmaceutical Company Limited
    Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven
    biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit http://www.asiamerlion.cn.

    Media Contacts:
    Japanese Media
    Kazumi Kobayashi
    kazumi.kobayashi@takeda.com
    +81 (0) 3-3278-2095

    Media Outside Japan
    Holly Campbell
    holly.campbell@takeda.com
    +1 617-588-9013

    Attachment

     

    Takeda To Appoint Another Representative Director


    As detailed below, Takeda Pharmaceutical Company Limited (“Takeda”) today announced that its Board of Directors has resolved to appoint another Representative Director at a Board of the Directors meeting immediately following the 145th Ordinary General Meeting of Shareholders where Directors who are not members of the Audit and Supervisory Committee are to be elected to the Board of Directors on June 29, 2021.

     

    1. Reason for the appointment

    Takeda has decided to establish a new role to chair and coordinate a network representing all Takeda's functions in Japan to maintain and enhance its reputation in Japan and to ensure one voice to its external stakeholders in Japan.

     

    1. Name and title of new representative director

    Name

    New Role (anticipated effective date, June 29, 2021)

    Prior  Role (appointed on April 1, 2021)

    Masato Iwasaki

    Representative Director, Japan General Affairs

    Director, Japan General Affairs

     

    1. Career summary of new representative director

    Date of birth

    Career summary, and position and responsibilities at the Company

    Number of shares owned

    November 6, 1958

    April 1985

    April 2008


    January 2012


    April 2012


    June 2012

    April 2015

    April 2021

    Joined the company

    Senior Vice President, Strategic Planning Department of the Company

    Head of CMSO Office, Takeda Pharmaceuticals International Inc.

    Senior Vice President, Pharmaceutical Marketing Division of the Company

    Director of the Company (to present)

    President, Japan Pharma Business Unit of the Company

    Japan General Affairs

    45,996 shares

     

    1. Anticipated Effective Date

    June 29, 2021

    国产AV网站_中午文字幕av一区二区三区_性进入裸体视频_久久久久久精品免费免费直播